<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226133</url>
  </required_header>
  <id_info>
    <org_study_id>D&amp;D CIP-0030</org_study_id>
    <nct_id>NCT02226133</nct_id>
  </id_info>
  <brief_title>Video-Assisted Left Atrial Appendage Exclusion Trial</brief_title>
  <acronym>VALET</acronym>
  <official_title>A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery (&quot;VATS&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LAAx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LAAx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exclusion of the LAA(Left Atrial Appendage) using the TigerPaw II System with VATS technique&#xD;
      is safe and effective.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this confirmatory study is to demonstrate that the LAAx, Inc. TigerPaw® II&#xD;
      System can be safely and effectively used to exclude the Left Atrial Appendage (LAA) during&#xD;
      cardiac surgery utilizing thoracoscopic camera and light source and thus remove, from the&#xD;
      cleared indication for use, the direct vision limitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    stopped for operational reasons&#xD;
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of device related adverse and serious adverse events</measure>
    <time_frame>30 (plus or minus 7) days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exclusion of the Left Atrial Appendage</measure>
    <time_frame>30 days</time_frame>
    <description>Primary effectiveness will be measured by the percentage of patients with exclusion of the LAA assessed intraoperatively via endoscopic image and transesophageal echocardiography (TEE).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Exclusion of Left Atrial Appendage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAAx, Inc. TigerPaw® System II</intervention_name>
    <description>Exclusion of Left Atrial Appendage.</description>
    <arm_group_label>Exclusion of Left Atrial Appendage</arm_group_label>
    <other_name>LAAx,Inc. TigerPaw System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Greater than or equal to 18 years of age;&#xD;
&#xD;
          2. Capable and willing to give informed consent;&#xD;
&#xD;
          3. Able and willing to complete a 30 day ± 7 day follow-up evaluation;&#xD;
&#xD;
          4. Ejection fraction ≥ 30%;&#xD;
&#xD;
          5. Life expectancy of &gt; 1 year;&#xD;
&#xD;
          6. Stroke Risk (CHADS score of ≥ 1), CHADS scoring: CHF=1 point, Hypertension (or treated&#xD;
             hypertension) = 1 point, Age &gt; 75 = 1 point, Diabetes = 1 point, Prior stroke or TIA =&#xD;
             2 points;&#xD;
&#xD;
          7. Subjects suitable for elective Video-Assisted Thoracoscopic Surgical (VATS)&#xD;
             procedure(s) including, but not limited to, cardiac surgery for one or more of the&#xD;
             following:&#xD;
&#xD;
               1. mitral valve repair or replacement,&#xD;
&#xD;
               2. aortic valve repair or replacement,&#xD;
&#xD;
               3. tricuspid valve repair or replacement,&#xD;
&#xD;
               4. coronary artery bypass procedures,&#xD;
&#xD;
               5. concomitant surgical (ablation or cut and sew) Maze procedure and other ablation&#xD;
                  procedures&#xD;
&#xD;
               6. hybrid procedures including combination surgical and interventional procedures&#xD;
                  and surgical procedures with a combination of left and right thoracic access&#xD;
                  sites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous cardiac surgery;&#xD;
&#xD;
          2. Active systemic or cutaneous infection or inflammation;&#xD;
&#xD;
          3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids not&#xD;
             including intermittent use of inhaled steroids for respiratory diseases;&#xD;
&#xD;
          4. Known, significant history of bleeding diathesis, coagulopathy, von Willebrand's&#xD;
             disease or current platelet count &lt; 100,000 cells/mm3, baseline INR ≥1.8, or&#xD;
             fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24&#xD;
             hours);&#xD;
&#xD;
          5. Severe co-existing morbidities having a life expectancy of less than 1 year;&#xD;
&#xD;
          6. Currently involved in any other investigational clinical trials that have not&#xD;
             completed their primary endpoint or that may interfere with the TigerPaw study&#xD;
             results;&#xD;
&#xD;
          7. Thrombus in the LAA/LA;&#xD;
&#xD;
          8. NYHA Class IV heart failure symptoms;&#xD;
&#xD;
          9. Mental impairment or other conditions which may not allow the subject to understand&#xD;
             the nature, significance and scope of the study and to cooperate with follow-up&#xD;
             requirements;&#xD;
&#xD;
         10. Preoperative need for an intra-aortic balloon pump;&#xD;
&#xD;
         11. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than&#xD;
             30%;&#xD;
&#xD;
         12. Females who are pregnant, planning to become pregnant within 1 month of the procedure,&#xD;
             or lactating;&#xD;
&#xD;
         13. Extreme morbid obesity (BMI greater than 45 kg/m2);&#xD;
&#xD;
         14. Any active medical condition that would preclude the patient from completing the study&#xD;
             or would result in an unreasonable risk;&#xD;
&#xD;
         15. Contraindication to Transesophageal Echocardiography (TEE);&#xD;
&#xD;
         16. Need for emergent cardiac surgery (e.g., cardiogenic shock);&#xD;
&#xD;
         17. Creatinine &gt;200 umol/L;&#xD;
&#xD;
         18. Renal failure requiring dialysis or hepatic failure;&#xD;
&#xD;
         19. A known drug and/or alcohol addiction;&#xD;
&#xD;
         20. Concurrent chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ValleyCare Health System-Pleasanton</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMD School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Heart Institute</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau MOB East</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>August 23, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>May 1, 2015</last_update_submitted>
  <last_update_submitted_qc>May 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

